This proposal seeks to expand experiments on characterizing ethanol withdrawal with respect to its symptoms and their mechanisms. Abuse of ethanol produces dependence characterized by a pattern of withdrawal consisting of subjective symptoms such as anxiety. Although the key role of these symptoms in initiating and maintaining ethanol abuse is well recognized, animal research on the subjective symptoms has been difficult. In the current funding period, it was demonstrated that ethanol withdrawal produces a PTZ-like internal stimulus that can be used to produce parametric data on the subjective symptoms of withdrawal. The HZ-like stimulus occurring during ethanol withdrawal was modulated by drugs acting at the gamma-amino butyric acid-type A (GABAA) receptor- chloride ion channel complex. However, PTZ-IDS was insensitive to modulation of brain serotonin (5HT) systems. The 5HT systems have been implicated in ethanol dependence and found important in our own experiments employing other behavioral measures. In order to better characterize the role of 5HT in the development of ethanol dependence and withdrawal using drug discrimination approach, new experiments are proposed to employ a 5HT agonist, 1(3-chlorophenyl)piperazine, mCPP, as a discriminative stimulus to characterize an animal model of the withdrawal symptoms. It is proposed: 1) to demonstrate that the mCPP IDS in animals is modulated by drugs which are either anxiogenic or anxiolytic in humans, 2) to demonstrate and characterize the spontaneous occurrence of a mCPP-like stimulus during ethanol withdrawal in relation to the intensity of the stimulus as a function of cumulative ethanol dose, 3) to modify the withdrawal stimulus by selected 5HT receptor subtype agonists and antagonists, and 4) to compare and contrast the PTZ and mCPP stimuli during ethanol withdrawal to determine the manner in which the 5HT and GABA systems relate to one another in producing """"""""anxiety""""""""-like behavior. Use of this method will provide important new data and extend the results obtained in our other animal models of anxiety. This research is significant because it provides information directly related to etiology and treatment of ethanol abuse.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Research Project (R01)
Project #
1R01AA010545-01
Application #
2047193
Study Section
Special Emphasis Panel (SRCA (44))
Project Start
1995-06-01
Project End
1998-05-31
Budget Start
1995-06-01
Budget End
1996-05-31
Support Year
1
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of North Texas
Department
Pharmacology
Type
Schools of Osteopathy
DUNS #
110091808
City
Fort Worth
State
TX
Country
United States
Zip Code
76107
Gatch, Michael B (2006) Tolerance to the antinociceptive effects of ethanol during ethanol withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 30:946-52
Gatch, Michael B; Jung, Marianna E; Wallis, Cleatus J et al. (2002) Effects of GABA(A) compounds on mCPP drug discrimination in rats. Life Sci 71:2657-65
Gatch, Michael B (2002) Nitrendipine blocks the nociceptive effects of chronically administered ethanol. Alcohol Clin Exp Res 26:1181-7
Gatch, Michael B; Selvig, Meghan (2002) Theophylline blocks ethanol withdrawal-induced hyperalgesia. Alcohol Alcohol 37:313-7
Gatch, M B; Wallis, C J; Lal, H (2001) Effects of calcium channel blockers on pentylenetetrazol drug discrimination in rats. Alcohol 23:141-7
Jung, M E; Wallis, C J; Gatch, M B et al. (2000) Sex differences in nicotine substitution to a pentylenetetrazol discriminative stimulus during ethanol withdrawal in rats. Psychopharmacology (Berl) 149:235-40
Jung, M E; Wallis, C J; Gatch, M B et al. (2000) Abecarnil and alprazolam reverse anxiety-like behaviors induced by ethanol withdrawal. Alcohol 21:161-8
Gatch, M B (1999) Effects of benzodiazepines on acute and chronic ethanol-induced nociception in rats. Alcohol Clin Exp Res 23:1736-43
Jung, M E; Wallis, C J; Gatch, M B et al. (1999) Sex differences in the pentylenetetrazol-like stimulus induced by ethanol withdrawal. J Pharmacol Exp Ther 291:576-82
Wallis, C J; Lal, H (1998) A discriminative stimulus produced by 1-(3-chlorophenyl)-piperazine (mCPP) as a putative animal model of anxiety. Prog Neuropsychopharmacol Biol Psychiatry 22:547-65